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Aim: To review the currently available literature comparing the FEV1/FVC <LLN with a fixed
value of FEV1/FVC <0.70 in diagnosing airflow obstruction in subjects aged >40 years.
Methods: A structured MEDLINE, EMBASE and Cochrane search of English-language literature
was conducted. Studies comparing prevalence rates according to the LLN and a fixed value
were included. Attention was paid to the choice of the reference test or gold standard used.
Results: Eighteen studies met the inclusion criteria. Sixteen studies compared the rates of
subjects diagnosed with airflow obstruction by either definition of airflow obstruction without
using a non-independent reference standard (level 4 studies). Using a fixed value of FEV1/FVC,
an overall higher number of subjects were diagnosed with airflow obstruction that increased
with age. Two studies included a follow-up phase comparing risks of either hospitalization
or occurrence of respiratory symptoms and mortality (level 2b studies). Adjusted risks of hospi-
talization (HR 2.6) or mortality (HR 1.3) were significantly larger in subjects with an FEV1/FVC
below 0.70 but above the LLN (in-between group) compared to subjects with normal lung func-
tion.
Conclusion: The prevalence of spirometry-based COPD is greater when using the fixed value of
FEV1/FVC in comparison to using the LLN. Based on one longitudinal study the in-between
group appears to have a higher risk of hospitalization and mortality; therefore it seems that
using the LLN of FEV1/FVC underestimates COPD. In absence of a gold standard of COPD longi-
tudinal research will be necessary to determine which criterion is better and more clinically
relevant.
ª 2011 Elsevier Ltd. All rights reserved.755 6151; fax: þ31 88 755 5415.
cht.nl (P. Zanen).
1 Elsevier Ltd. All rights reserved.
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Figure 1 Flowchart search strategy. Search performed June
2010.
908 F.A.A. Mohamed Hoesein et al.Introduction
Chronic obstructive pulmonary disease (COPD) will consti-
tute the third leading cause of death by 2020 and it is
currently the only chronic disease with increasing mortality
rates.1 COPD is preventable but irreversible and stabilizing
the progression of the disease in an early phase appears to
be the best therapy for decreasing morbidity and mortality
and reducing health costs.2 Consensus on the proper diag-
nostic criteria for COPD is essential.
It is widely accepted that the presence of airflow
obstruction is key in diagnosing COPD.2,3 Airflow obstruc-
tion is present when the forced expiratory flow in 1 s
(FEV1)/forced vital capacity (FVC) e ratio is reduced.
3
Another important sign of COPD is a decline in FEV1 which
is consequently used as a measure of the severity of airflow
obstruction.2
There is still a controversy regarding the appropriate
cut-off values for FEV1/FVC.
4e6 In 2001, the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD)
committee was the first to publish a consensus statement
propagating the use of a fixed FEV1/FVC <0.70 value and
fixed FEV1 values to classify severity.
7 One of the objectives
in introducing fixed values was to standardize and increase
the awareness of diagnosing COPD, i.e. to simplify the
diagnosis. However, more recently the GOLD committee
recognized that using a fixed value of <0.70 may lead to
potential overdiagnosis in the elderly.2
In 2004, the ERS and the ATS issued a combined state-
ment advocating the use of the lower limit of normal (LLN)
instead of a fixed criterion.8 The LLN is statistically defined
by the lower fifth percentile of a reference population and
can be calculated by subtracting 1.64 times the standard
deviation from the mean, i.e. the expected value. The LLN
is age-corrected. Using a fixed percentage instead of the
LLN has several drawbacks as mentioned by Pellegrino
et al.4 One of the main arguments for discarding the fixed
FEV1/FVC criterion is that it can lead to a COPD diagnosis in
non-smoking elderly.9
A large number of studies have compared the two COPD
definitions in an attempt to decide which is more appro-
priate. This review aims to clarify the strengths and
weaknesses of studies comparing the LLN with a fixed
criterion. We focused on the study design and the choice of
reference tests that were employed in these studies.Methods
Search strategy
A structured search was conducted in Medline, EMBASE and
the Cochrane library containing studies from January 1966Table 1 Search strategy used in MEDLINE, EMBASE and Cochran
Search terms
“Lower limit of normal” OR “lower limits of normal” OR LLN OR
OR “5th percentile”till June 2010. The search strings that were used contained
synonyms and related terms for the “lower limit of
normal”. The Boolean operator “OR” was used to combine
the search terms; the complete search string is noted in
Table 1. Moreover, all references from the bibliographies of
the included articles were reviewed.
Article inclusion
After removing duplicates, F.M.H. and P.Z. independently
screened all articles’ titles and abstracts by applying
inclusion and exclusion criteria (see flowchart, Fig. 1).
Articles were included if (a) they pertained to studies
comparing the LLN with a fixed criterion to diagnose
spirometry-based COPD, (b) spirometry was performed in
an adult population containing subjects 40 years and (c)
they were written in English. If the abstract alone did not
provide sufficient information to conclude that the article
compared the LLN with a fixed value of FEV1/FVC, the full-
text was retrieved. Differences with respect to article
inclusion were resolved by consensus between the two
reviewers. Full-text versions of the included articles were
retrieved if available and were read independently by both
reviewers.e library June 2010.
Results
“fifth percentile” OR “five percentile” 1954
Lower limit of normal or FEV1/FVC <0.70: A review 909Study appraisal
All included articles were appraised independently by
F.M.H. and P.Z. on criteria concerning validity: (a) design,
(b) study population, (c) presence or choice of a gold
standard or reference test and (d) subject inclusion. Special
attention was paid to the choice of the reference test/gold
standard used. It was noted whether (1) only prevalence
was reported according to either definition while no
reference standard was used, (2) either one of the defini-
tions was used as a reference test or (3) another kind of
reference standard, like follow-up or a range of tests, was
used. Levels of evidence were classified according to
Oxford Centre for Evidence-based Medicine (CEBM) levels
of evidence, see Table 2.10 Disagreement in study appraisal
was resolved by consensus.
Data extraction
The reviewers independently extracted the following data:
(a) number of subjects included, (b) percentage of males,
(c) mean ages (standard deviation), (d) percentage of
current smokers and (e) prevalence of COPD according to
LLN and fixed FEV1/FVC criteria. If it was not provided, the
percentage of smokers and prevalence rates were calcu-
lated by using the data provided in the text and tables of
the article. Differences in the extracted data were resolved
by consensus between the two reviewers.
Results
General
The search of the three databases yielded 1954 individual
articles. After applying the inclusion criteria on the titles and
abstracts, 30 articles were selected and the full-texts were
retrieved. Two articles were not available as full text.11,12
Eleven articles were excluded after full-text screening
because they did not meet the inclusion criteria. Screening
of the references resulted in one additional publication.13 In
total, 18 articles were included as is mentioned in the flow-
chart search strategy (Fig. 1). In Table 3, the authors, year of
publication, number of included patients, percentage of
males, study population, reference equation used for
calculating predicted lung function and LLN, age groups,
smoking status, and use of post-bronchodilator values were
noted separately for each included study.Table 2 Levels of evidence according to the Oxford Centre for
Level
1a Systematic reviews with homogeneity or studies with
1b Validating cohort studies with good reference standar
1c Studies reporting high sensitivity/specificity
2a Systematic reviews with homogeneity of Level >2 stu
2b Systematic reviews with homogeneity or studies with
3a Systematic reviews with homogeneity of Level >3 stu
3b Non-consecutive studies or without consistently applie
4 Caseecontrol studies, poor or non-independent refere
5 Expert opinionSix studies performed post-bronchodilator spirometry.14e19
The majority of the studies compared the fixed value of FEV1/
FVC<0.70 against the LLN and thus used the LLN as their gold
standard or reference test, see Table 4. Only Mannino et al.
used occurrence of COPD-based hospitalization and mortality
during follow-up as a reference, while Vaz Fragoso used
mortality and occurrence of respiratory symptoms as a refer-
ence.20,21 The remaining studies provided prevalence and
discordance rates according to either definition, see Table 4.
The CEBM levels of evidence are provided in Table 4.
Clinically based studies
Five studies were clinically based, i.e. including only
referred or hospitalized subjects, and all had a cross-
sectional design.13,14,22e24 All five studies included subjects
over a wide age range, but unfortunately prevalence rates
according to either definition were not consistently divided
by age groups. Only the study by Schermer et al. provided
separate rates for subjects aged 51e60; 61e70 and 71
years: it was the only clinically based study to include post-
bronchodilator spirometry values.14 Prevalence rates
according to a fixed FEV1/FVC of <0.70 were higher in these
age groups than the prevalence rates according to the LLN,
which ranged from 27.5% to 45% and from 20% to 25%,
respectively. Discordant prevalence rates occurred in 4% up
to 20% of the cases in this study.
Aggarwal et al. found an overall lower prevalence rate
when applying FEV1/FVC <0.70 instead of the LLN, 23.6%
and 28.2% respectively.22 This stands in contrast to the
other studies, but it should be noted that they included
younger subjects. The studies by Margolis et al., Dejsom-
ritrutai et al. and Roberts et al. found overall higher
prevalence rates when FEV1/FVC <0.70 was used rather
than the LLN (Table 4).13,23,24 Discordant results in these
three studies occurred in 6%, 7.5% and 14.7% of the cases
respectively. All five articles mentioned in their discussion
the observation of growing prevalence differences between
the two definitions based on increasing age, although exact
numbers were not provided.
Population-based studies
Thirteen population-based studies were included.15e21,25e30
Six studies used the NHANES III study population.21,25e27,30,31
Three studies were performed in an Asian population.15,16,28Evidence-based Medicine Levels of Evidence (CEBM).10
clinical prediction rule from different clinical centres
ds or studies with clinician prediction rule within one centre
dies
clinical prediction rule from different clinical centres
dies
d reference standards
nce standard
Table 3 Overview of included studies with year of publication, number of included patients, percentages of males, age groups included, smoking status of included subjects
and use of post-bronchodilator values.
Study Year Subjects no. Male [%] Population Reference equation
used
Mean age
(SD) [yr]
Age
range [yr]
Post-
bronchodilator
Smokers
[%]
Never
smokers [%]
Referred/
hospitalized
subjects
Aggarwal et al.22 2006 18,112 56.1 India Jindal et al.a M 48.2 (16.2)/
F 44.8 (14.8)
15 No NA NA
Dejsomritrutai et al.23 2002 1754 54.1 Thailand Dejsomritrutai et al.b NA 1291 NA NA
Margolis et al.13 1997 166 95.1 USA Crapo et al.c 58.9 (13) 24 No 43 11
Roberts et al.24 2006 1503 47 USA Hankinson et al.,d
Crapo et al.,c
Knudson et al.e
NA 20 No NA NA
Schermer et al.14 2008 14,056 47 Netherlands Quanjer et al.f M 54.2 (15.2)/
F 51.9 (15.1)
21 Yes NA 31
Subjects from
general
population
Celli et al.25 2003 9838 47.8 NHANES III Hankinson et al.d 48.3 (13.6) 30 No 30.3 42.8
Hansen et al.26 2007 9508 43.1 NHANES III Hankinson et al.d NA 20e80 No 36.8 62.8
Hnizdo et al.27 2006 13,842 NA NHANES III Hankinson et al.d NA 20e80 No NA NA
Hwang et al.15 2009 2728 46.3 Korea Hwang et al.g 41 (median) 18 Yes 28.9 NA
Ko et al.16 2008 1008 26.9 China Ip et al.h 74.2 (6.4) 60 Yes 4.5 74.9
Lau et al.28 2007 525 100 Hong Kong Ip et al.h NA 20e80 No 68.3 0
Mannino et al.20 2007 4965 43.0 CHS Hankinson et al.d NA 65 No 11.6 45.9
Perez-Padilla et al.19 2007 5183 40.0 PLATINO Perez-Padilla et al.i 56.2 40 Yes NA NA
Roche et al.29 2008 4764 48.1 France Quanjer et al.f 59.9 (10.1) 45 No 18.1 48.2
Shirtcliffe et al.17 2004 749 54.2 New Zealand Marsh et al.j 54.9 (12.8) 30 yes 10.1 46.2
Swanney et al.30 2008 40,646 NA NHANES III/
HSE9596/Dutch
Hankinson et al.d NA 17 No NA NA
Vaz Fragoso et al.21 2010 2480 49.5 NHANES III Hankinson et al.d 71.7 (4.5) 65e80 No 15.0 44.7
Vollmer et al.18 2009 10,001 47.7 BOLD Hankinson et al.d NA 40 Yes 57.1 42.9
NHANES IIIZ Third National Health and Nutrition Examination Survey, BOLDZ Burden of Lung Disease Initiative, CHSZ Cardiovascular Health Study, HSE9596ZHealth Survey for England
1995e1996.
a Jindal SK, Wahi PL. Pulmonary function laboratory in the tropics: needs, problems and solutions. In: Sharma OP. Lung disease in the tropics. New York: Marcel Dekker; 1991.
p. 523e542.
b Dejsomritrutai W, Nana A, Maranetra KN et al. Reference spirometric values for healthy lifetime nonsmokers in Thailand. J Med Assoc Thai 2000; 83(5):457e466.
c Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123(6):659e664.
d Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159(1):179e187.
e Knudson RJ, Lebowitz MD, Holberg CJ et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127(6):725e734.
f Quanjer PH, Tammeling GJ, Cotes JE et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and
Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 16(Suppl):5e40.
g Hwang YI, Kim CH, Kang HR et al. Comparison of the prevalence of chronic obstructive pulmonary disease diagnosed by lower limit of normal and fixed ratio criteria. J Korean Med Sci
2009; 24(4):621e626.
h Ip MS, Ko FW, Lau AC et al. Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest 2006; 129(2):384e392.
i Perez-Padilla R, Valdivia G, Muino A et al. Spirometric reference values in 5 large Latin American cities for subjects aged 40 years or over. Arch Bronconeumol 2006; 42(7):317e325.
j Marsh S, Aldington S, Williams M et al. Complete reference ranges for pulmonary function tests from a single New Zealand population. N Z Med J 2006; 119(1244):U2281.
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Lower limit of normal or FEV1/FVC <0.70: A review 911The studies byMannino et al., Roche et al., Vollmer et al. and
Vaz Fragoso included only subjects 40 years.18,20,21,29 Five
studies performed post-bronchodilator spirometry.16e19,28 In
all other population-based studies only pre-bronchodilator
values were used. Prevalence rates were higher in all studies
after applying an FEV1/FVC <0.70 and the differences grew
with increasing age (Table 4). Prevalence rates according to
FEV1/FVC increased more with age than did the prevalence
rates according to LLN.
The study by Mannino et al. had a longitudinal design
with mortality and COPD-related hospitalization as the
primary outcomes.20 4965 subjects (age >65 years) from
the Cardiovascular Health Study (CHS) were included and
were followed for nine years. The subjects were classified
according to the FEV1/FVC <0.70 or LLN. 1134 subjects had
an FEV1/FVC <0.70, but >LLN (in-between group). Subjects
in the in-between group had a higher adjusted mortality
risk (HR 1.3, CI95% 1.1e1.5) and an increased COPD-related
hospitalization (HR 2.6, CI95% 2.0e3.0) in comparison to
subjects with normal lung function. The outcome suggests
that using the FEV1/FVC <0.70 identifies at-risk patients
who would have been classified as normal according to LLN.
Vaz Fragoso et al. assessed data of 2480 subjects, aged
65e80, who were followed for 12 years and compared the
risks of all-cause mortality and on respiratory symptoms
between subjects with an FEV1/FVC <0.70 and <LLN (<5th
percentile).21 831 subjects had an FEV1/FVC <0.70, and
179 of these also had an FEV1/FVC <LLN. The adjusted
hazard ratio of all-cause mortality in <LLN subjects was
2.01(95%CI 1.60e2.54) and 1.24(95%CI 1.04e1.47) for those who had
<0.70 compared to those with normal lung function. The
authors found no significant effects of either classification
on the risk of respiratory symptoms being present. This
outcome suggest that those with <0.70 have a lower risk of
all-cause mortality compared to those with <LLN, yet the
risk is still higher than those with normal lung function.
Comparing healthy never-smokers and current
smokers
Vollmer et al., Hansen et al., Roche et al. and Swanney
et al. also compared healthy never-smokers and found that
COPD prevalence rates were higher when using a fixed
value of FEV1/FVC <0.70.
18,26,29,30 These differences
increased especially with increasing age. The study by
Vollmer et al. used post-bronchodilator values, but unfor-
tunately only numbers for the non-smokers and not for the
current smokers were reported.18
Discussion
This evidence-based review presents an overview of studies
comparing the FEV1/FVC <LLN with FEV1/FVC <0.70 in
diagnosing spirometry-based COPD. The majority of studies
reviewed had a cross-sectional design and all concluded
that using the <0.70 approach resulted in a greater prev-
alence of COPD, which was often interpreted as ‘over-
diagnosing COPD’. As mentioned by Vollmer et al., using the
LLN as a threshold would probably miss subjects with mild
airflow obstruction, but would correctly diagnose subjects
with more profound and advanced airflow obstruction.18Taking this into consideration we have to ponder whether
we can afford to miss those subjects who have only mild
airflow obstruction since treatment options already may be
present at an early stage.
Based on Table 4 it can be concluded that 13 out of 18
researchers made the a priori choice to adopt the LLN as
their reference test. Unfortunately, this approach is flawed
because the outcome of the comparison becomes predict-
able. Instead, the correct approach should be to select the
diagnostic test that outperforms the other when both are
tested against a gold standard. Unfortunately that golden
standard test for COPD is lacking in all cases. The GOLD
committee states that their cut-off points for COPD have
not been clinically validated.
Ideally, the gold standard should be the perfect diag-
nostic test with a sensitivity and specificity of 100%. By
adopting LLN as a reference or standard, one implicitly
declares that this test is the gold standard and that any
other test (e.g. the <0.70 approach) can deliver a maximal
sensitivity/specificity of 100%, i.e. deliver equivalent
results as the gold standard in terms of diagnosing or ruling
out COPD. When the LLN is a “less than perfect” gold
standard, and thus sometimes misdiagnoses or misses COPD
as a result, one implicitly expects the new test to make the
same mistakes in its attempt to deliver a maximal sensi-
tivity/specificity of 100%. Even when the new test is
“perfect”, a comparison with a “less than perfect” test will
deliver a sensitivity/specificity <100% and thus be inclined
to regard the new test as being inferior. This is known as an
‘imperfect gold standard bias’ and is an important concept
to bear in mind when interpreting the outcomes of such
studies.32 Reversing the choices by adopting the FEV1/FVC
<0.70 as the reference would predictably lead to a sensi-
tivity/specificity <100% of the LLN. The only valid conclu-
sion one may draw when comparing diagnostic tests without
a gold standard, is that they may produce different results.
A conclusion regarding superiority or inferiority is not
possible.
Some of the included studies did not report sensitivity
and specificity values but provided agreement stated as
kappa. Kappa is used to depict the extent of agreement
between tests and its value ranges from 0 (no agreement)
to 1 (perfect agreement). Again, in the absence of a gold
standard, one should be cautious when interpreting kappa
because in case of good agreement, one can only conclude
that two tests are equivalent, not that either one is
correct. As a consequence, due to the lack of a gold stan-
dard, the level of evidence according to the CEBM is 4.
A longitudinal study is probably the best option for
obtaining a correct COPD diagnosis: time will tell whether
or not a smoker’s lung function declines. The decline in the
lung function can be compared with the lung function of
a never-smoker and the decline in lung function becomes
the gold standard. Unfortunately, only two longitudinal
studies were performed comparing the risks of hospitali-
zation, the occurrence of respiratory symptoms and the
mortality of subjects diagnosed with an FEV1/FVC <0.70
or <LLN.20,21 The study by Mannino et al. showed that
subjects with an FEV1/FVC <0.70 but above the LLN had
increased hospitalization and mortality rates, with hazard
ratios of 2.6 and 1.3, respectively. At the same time,
the study by Vaz Fragoso showed that subjects with an
Table 4 Prevalence of airflow obstruction according to definition used, reference standard used, levels of evidence and conclusion of the authors.
Study Prevalence
GOLD [%]
Prevalence
LLN [%]
Reference
standard
Level of
evidence*
Authors conclusion/
recommendation
Referred/
hospitalized
subjects
Aggarwal et al.22 Overall: 23.6 Overall: 28.2 LLN 4 Use LLN instead of fixed criterion based
on statistical considerations
Dejsomritrutai et al.23 Overall: 51.5 Overall: 37.9 LLN 4 Fixed criterion result in poor agreement
with LLN. Use FEV1/FVC 90% of predicted
Margolis et al.13 Overall: 24.5 Overall: 24 None 4 Discrepancies in diagnosis between LLN
and fixed criterion exist
Roberts et al.24 Overall: 40 Overall: 37 LLN 4 At extreme age using fixed criterion leads
to higher prevalence of airflow obstruction
when compared to LLN
Schermer et al.14 51 to 81: 27.5e45 51 to 81: 20e25 LLN 4 Use LLN because fixed criterion leads
to overestimation
Subjects from
general
population
Celli et al.25 Overall: 25.6e41.7 Overall: 19.1e22.7 LLN,
self-reported
COPD
4 Discrepancies in diagnosis between LLN
and fixed criterion exist. Opinion leaders
should agree upon definition
Hansen et al.26 Sk: M 41.2e62.4;
F 50.1e18.8
Sk: M 32.2e42.9;
F 25.4e31.3
LLN 4 Discard fixed criterion because it leads to
overestimation of airflow obstruction in elderly
NvSk: M 9.8e26.3;
F 6.9e33.1
NvSk: M 4.6e6.0;
F 6.2e12.1
Hnizdo et al.27 50e80: 30.5 50e80: 19.2 LLN,
physician-
diagnosed
4 Using fixed criterion overestimates airflow
obstruction in subjects age >50
Hwang et al.15 45: 13.5; 75: 30.7 45: 10.7; 75: 16.4 LLN 4 Using LLN might reduce risk of overdiagnosis
in elderly
Ko et al.16 Overall: 25.9 Overall: 12.4 LLN,
symptoms
4 Longitudinal studies necessary to assess
appropriate definition formationSk: M 40.4; F 25.3 Sk: M 9.6; F 20.7
NvSk: M 21.0; F 23.1 NvSk: M 5.7; F 13.1
Lau et al.28 60e80: 45.4 60e80: 27.6 LLN 4 Use LLN calculated from local reference equation
Mannino et al.20 Overall: 42.1 Overall: 19.3 Follow-up:
mortality/
COPD-related
hospitalization
3b LLN may miss subjects likely to have complications
Perez-Padilla et al.19 14.0 10.8 None 4 No preference stated
Roche et al.29 Sk: 12.53 Sk: 9.13 None 4 No preference stated. Need for homogenizing
definition of airflow obstructionNvSk: 6.62 NvSk: 4.85
Shirtcliffe et al.17 40: 14.2 40: 9.0 LLN, self-
reported
COPD
4 Discrepancies in diagnosis between LLN and
fixed criterion exist. Longitudinal studies
necessary to determine correct definition
Swanney et al.30 Sk: M 41.2e62.4;
F 50.1e18.8
Sk: M 32.2e42.9;
F 25.4e31.3
LLN 4 Use LLN instead of fixed criterion. Perform
spirometry only in subjects with complaints
and prior tobacco exposure to avoid overdiagnosisNvSk: M 9.8e26.3;
F 6.9e33.1
NvSk: M 4.6e6.0;
F 6.2e12.1
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Lower limit of normal or FEV1/FVC <0.70: A review 913FEV1/FVC <LLN have higher risks of mortality compared to
those with <70%, with hazard ratios of 2.0 and 1.2
respectively. Unfortunately the latter study did not
examine the mortality risks of the in-between group.
The disadvantage of cross-sectional studies is that they
miss subjects with an accelerated decline in lung function,
which may still have >0.70 or >LLN: it is inevitable that
both measures will fall short in being the perfect diagnostic
tools in cross-sectional studies. The point in time at which
either of the two boundaries will be crossed partly depends
on the initial height of lung function: subjects with a high
initial lung function require more time to be labeled as
COPD-subjects even though their lung function can decline
as rapidly as in others. They remain ‘healthy smokers’ for
a longer time. When rapidly declining subjects with an
FEV1/FVC >0.70 are still labeled as ‘non-diseased’, a large
number of COPD-subjects will be missed.
The pattern of lung function decline is therefore an issue
in determining which of the two diagnostic tests is the least
imperfect under cross-sectional conditions. In their well-
known study Fletcher and Peto found that FEV1-decline was
initially small but became stronger as lung function
decreased.33 This phenomenon is referred to as the “horse-
racing effect”.34 By contrast, in the placebo-arms of the
UPLIFT and TORCH studies, two randomized controlled
studies (RCTs), lung function decline was more pronounced
initially and slowed down as lung function lowered.35,36
Both patterns of decline are schematically depicted in
Fig. 2. If the ‘Fletcher and Peto’ pattern is valid, subjects
will hover above both thresholds for longer periods of time
and in cross-sectional studies neither the FEV1/FVC <0.70
or <LLN will be able to discriminate sufficiently between
susceptible and non-susceptible smokers. On the other
hand, when the ‘UPLIFT and TORCH’ pattern is valid,
susceptible smokers will show rapid FEV1/FVC declines
initially and therefore cross the <70% threshold in an early
phase of their disease and the <LLN threshold in a later
phase. The risk of missing susceptible smokers in a cross-
sectional study will thus be lower using the FEV1/FVC <0.70
value, whereas for the FEV1/FVC <LLN more time will pass,
allowing greater lung function deterioration.
Another approach would be to distinguish those subjects
with respiratory symptoms from those without. It has been
shown that mild COPD subjects (GOLD stage I) without
respiratory symptoms show no significantly faster FEV1-
decline compared to those with normal lung function, i.e.
FEV1/FVC >70%.
37 These results suggest that the presence
of respiratory symptoms should be part of the definition of
COPD. Our review focused on literature including older
subjects, although one study conducted in younger subjects
is worth mentioning. The study by De Marco et al. included
subjects aged 20e44 years and compared FEV1-decline and
hospitalization rates according to definition of airflow
obstruction (<70% or <LLN).38 The outcome was that
subjects with respiratory symptoms had more significant
FEV1-decline than subjects without respiratory complaints,
regardless of which spirometric criteria were used.
An important and often cited argument for not using the
FEV1/FVC <0.70 threshold is the observation of high prev-
alence rates of COPD in elderly healthy never-smokers. This
argument is correct in our view, but at the same time is
valued too high. COPD screening in subjects without prior
Figure 2 Patterns of lung function decline: FEV1 decline
against FEV1 percentage of predicted. The horse racing effect:
FEV1 decline increases with decreasing FEV1 percentage of
predicted.
914 F.A.A. Mohamed Hoesein et al.tobacco addiction is less sensible.39 No physician will/may
label subjects without a prior smoking history and respira-
tory complaints as COPD based only on the outcomes of an
FEV1/FVC value.
The availability of population-specific reference equa-
tions is essential for the utilization of the LLN worldwide.
However, in many parts of the world, these population-
specific (post-bronchodilator) reference equations are not
(yet) established. Instead, reference equations based on,
for instance, the US-population like the NHANES III are
used. This may result in biased outcomes when applying in
non-US populations.
This present review has several limitations which need
some attention. First, the majority of included studies only
performed pre-bronchodilator spirometry. Differences in
prevalence of airflow obstruction, as defined by FEV1/FVC
<0.7 or <LLN, can be pre-/post-bronchodilator spirometry
study dependent. However, at the moment it is not possible
to estimate to what degree due to the lack of data. The few
studies that performed both pre- and post-bronchodilator
measurements did not report the pre-bronchodilator data.
Second, studies with inconclusive results may not have
been published and thus missed in our search. Third, two
articles were not available in full text.11,12 Fourth, an
English-language bias may be present because only the
English-language literature was searched. Seeing as these
limitations are similar to those encountered by the studies
included in this review, we believe that this will not affect
the validity of our conclusions.
Conclusion
A major shortcoming of the cited literature is that FEV1/FVC
<0.70 and <LLN were not compared to a gold standard.
However, defining such a standard is difficult. Nine out of the
18 included articles defined only the FEV1/FVC <LLN as their
reference test and they influenced theoutcome in favor of the
FEV1/FVC <LLN. Therefore, based on the current availableliterature it cannot be determined whether it is preferable to
use the LLN rather than to a fixed percentage of FEV1/FVC.
Nevertheless, the outcome of the only included longitudinal
study in which subjects with an FEV1/FVC<70% but>LLN are
compared to thosewith normal lung function suggest that LLN
maymiss subjects at risk. Further longitudinal researchwill be
necessary to determine which criterion is better and more
clinically relevant. Until then, neither of the two approaches
can be claimed to be superior over the other.
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